Geriatric Pharmacoepidemiology

((SLA-160)) (SLA-160) Magnitude and Patterns of Potential Diuretic Prescribing Cascades after Calcium Channel Blocker Initiation in Medicare Beneficiaries with and without Congestive Heart Failure

((SLA-161)) (SLA-161) Prevalence and Mortality of HIV-Associated Neurocognitive Disorder (HAND) in Older Medicare Beneficiaries

((SLA-162)) (SLA-162) The Prevalence of Central Nervous System-Active Polypharmacy in U.S. Nursing Homes During the COVID-19 Visitation Restriction

((SLA-163)) (SLA-163) Multidomain frailty index from routine health data and medication use in older patients with and without dementia in Australian hospitals

((SLA-164)) (SLA-164) Mortality in Patients With Parkinson’s Disease Psychosis Using Pimavanserin Versus Other Antipsychotics

((SLA-166)) (SLA-166) Effectiveness, Safety, and Costs of Initiating Gabapentin Versus Pregabalin among Older Adults with Chronic Opioid Use

((SLA-167)) (SLA-167) Antibiotic use and risk of inflammatory bowel disease in older adults: a nationwide self-controlled case series study

((A-145)) (A-145) The comparative risk of diagnosed depression among older men with metastatic castration resistant prostate cancer initiating enzalutamide versus abiraterone

((A-146)) (A-146) Development of Model for Predicting Early Mortality in Older Cancer Patients Treated with Chemotherapy

((A-147)) (A-147) Cardiovascular, Kidney, and Safety Outcomes following GLP-1 Receptor Agonist initiation in Adults with Alzheimer's Disease and Related Dementias: A Target Trial Emulation Study

((A-148)) (A-148) Differences in the prevalence of diagnosis code groups for comorbidities using Medicare Advantage encounter data and Fee-For-Service claims

((A-149)) (A-149) Comparing cancer screening prevalence among older adults in Medicare Advantage encounter data and Fee-For-Service claims

((A-152)) (A-152) Costs and Lost Time for Employees whose Spouses have Dementia and/or Alzheimer’s Disease and Patient Direct Costs

((A-153)) (A-153) The association between metformin-based regimens and cognitive performance in participants with type2 diabetes in the UK Biobank

((A-154)) (A-154) Predicting Response to Mono and Dual Antidementia Pharmacotherapy Among Nursing Home Residents

((A-155)) (A-155) Effect of statin discontinuation on mortality among older adults with and without cardiovascular disease

((A-156)) (A-156) Prescription and Non-Prescription Medication Use Before and After a Herpes Zoster Diagnosis Among Nursing Home Residents in the United States

((A-157)) (A-157) Psychotropic medication prescribing among older adults before and after dementia diagnosis: a retrospective study in Yinzhou, China

((A-158)) (A-158) Patterns of Long-Term Bisphosphonate Use and Drug Holiday Among U.S. Medicare Beneficiaries

((A-159)) (A-159) Relationship between sociodemographic factors and discontinuation of high-risk long-term medication in US older adults

((A-160)) (A-160) Antidepressant Use Among US Nursing Home Residents with ADRD in 2018

((A-161)) (A-161) Hospital admissions due to adverse drug reactions and adverse drug events in older adults: A systematic review

((A-162)) (A-162) Prospective Validation of the Adverse Drug Reactions in an Ageing Population Risk Prediction (ADAPTiP) tool and Comparison with Previously Described Risk Prediction Tools: Study Protocol

((B-141)) (B-141) Increased Incidence of Parkinson's Disease Associated with Antiseizure Medication Use

((B-142)) (B-142) Antithrombotic Treatment after Left Atrial Appendage Occlusion in Older Atrial Fibrillation Patients

((B-143)) (B-143) Discontinuation Pattern of Disease-modifying Therapies among Older Adults with Multiple Sclerosis

((B-144)) (B-144) Trends in Drug-Drug Interactions Among US Older Adults, 2015-2016 vs. 2021-2023

((B-145)) (B-145) Timing of Symptomatic Treatment Discontinuation on Neuropsychiatric and Functional Outcomes in Alzheimer's Disease and Related Dementias

((B-146)) (B-146) Double Burden: Anticholinergic and Sedative Medication Impact on Older Adults' Health Outcomes

((B-147)) (B-147) Impact analysis of the recent policy interventions for regional polypharmacy reduction in Japan with high older population: A nationwide serial cross-sectional study (April 2020-March 2023)

((B-148)) (B-148) REpositioning of Medications IN Dementia (REMIND): Evaluating fitness for purpose of the SNDS French nationwide claims database

((B-149)) (B-149) Constructing a frailty index (FI) using the Behavioral Risk Factor Surveillance System: Application in lung cancer screening

((B-150)) (B-150) Determinants Associated with Use of Angiotensin II Inhibiting vs Angiotensin II Stimulation Antihypertensive Medications among Medicare Beneficiaries

((B-151)) (B-151) Difference in Awareness of Osteoporosis and Bone Mineral Density Testing between Older Men and Women

((B-152)) (B-152) AI-Assisted Medication Management: Reducing Risks and Costs in Hyper-Polypharmacy Patients

((B-153)) (B-153) Improving Quality-of-Care and Preventing Iatrogenesis for a Healthy Ageing – A Survey on Portuguese Healthcare Professionals

((B-154)) (B-154) A Qualitative Study on Iatrogenesis: Perspectives from Healthcare Professionals

((B-155)) (B-155) Disparities in Nonpharmacologic Chronic Pain Treatments for Older Adults with Alzheimer’s disease and Related Dementias

((B-156)) (B-156) Motor Vehicle Crash Risk in Older Adults with Alzheimer’s Disease After Acetylcholinesterase Inhibitor Initiation: A Sequential Target Trial Emulation

((B-157)) (B-157) Aetiology, Prevalence and Pharmacological Management of Rheumatoid Arthritis among geriatrics at Kenyatta National Hospital (2018-2022)

((B-158)) (B-158) Central Nervous System (CNS) medication use patterns before suicide among older adults